Index of /~bryan/papers2/gene-therapy

[ICO]NameLast modifiedSizeDescription
[PARENTDIR]Parent Directory  -  
[TXT]url.txt2018-03-17 13:37 1.0K 
[DIR]urine-pigmentation/2010-01-17 08:33 -  
[ ]siRNA vs. shRNA - Similarities and differences.pdf2010-01-14 16:20 1.5M 
[TXT]notes.txt2010-01-14 15:41 3.3K 
[DIR]non-integrating-lentivirus/2018-03-17 11:58 -  
[TXT]get.txt2018-03-16 10:36 2.5K 
[TXT]gene_therapy.wikipedia.txt2010-01-14 15:41 47K 
[ ]Unraveling the complex story of immune responses to AAV vectors trial after trial - 2017.pdf2018-03-16 10:20 437K 
[ ]Two decades of clinical gene therapy - success is finally mounting - 2010.pdf2016-07-26 10:32 1.5M 
[ ]Therapeutic genome editing: prospects and challenges - 2015.pdf2016-07-26 10:35 444K 
[ ]Therapeutic application of RNAi - is mRNA targetting finally ready for the prime time - 2007.pdf2010-01-14 16:16 495K 
[ ]The ideal gene delivery vector: Chromallocytes, cell repair nanorobots for chromosome replacement therapy - Freitas - 2007.pdf2007-06-12 10:52 449K 
[ ]Targeted plasmid integration into the human genome by an engineered zinc-finger recombinase - 2011.pdf2018-03-15 14:48 2.8M 
[ ]Systemic gene delivery to the central nervous system using Adeno-associated virus - 2014.pdf2016-10-22 07:50 824K 
[ ]Structure-guided evolution of antigenically distinct adeno-associated virus variants for immune evasion - 2017.pdf2018-03-16 10:05 2.7M 
[ ]Strategies to circumvent humoral immunity to adeno-associated viral vectors - 2015.pdf2018-03-16 10:16 185K 
[ ]Safety and efficacy of gene transfer for Leber's congenital amaurosis.pdf2010-01-14 15:54 600K 
[ ]Retrovirus-mediated single-cell gene knockout technique in adult newborn neurons in vivo.pdf2009-08-12 07:44 221K 
[ ]Progress towards in vivo use of siRNAs.pdf2010-01-14 16:14 355K 
[ ]Programmable genome editing tools and their regulation for efficient genome engineering - 2017.pdf2017-02-19 20:15 1.1M 
[ ]Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy - 2013.pdf2018-03-16 09:49 273K 
[ ]Pharmacological modulation of humoral immunity in a nonhuman primate model of AAV gene transfer for hemophilia B - 2012.pdf2018-03-16 09:50 231K 
[ ]Overview of gene therapy and viral vectors for CNS applications - Martha Bohn - 2005.pdf2011-01-16 06:31 319K 
[ ]Overcoming preexisting humoral immunity to AAV using capsid decoys - 2013.pdf2018-03-16 09:52 1.5M 
[ ]Optimization of PAMAM-gold nanoparticle conjugation for gene therapy - 2015.pdf2017-01-10 17:55 4.1M 
[ ]Non-viral vectors for gene-based therapy - review - 2014.pdf2016-07-26 10:33 2.8M 
[ ]Non-viral nucleic acid delivery strategies to the central nervous system - 2016.pdf2017-01-10 18:33 1.6M 
[ ]Naturally enveloped AAV vectors for shielding neutralizing antibodies and robust gene delivery in vivo - 2014.pdf2018-03-16 09:54 1.8M 
[ ]Nanoparticles as a tool for transfection and transgenesis - A review - 2016.pdf2017-12-30 19:27 253K 
[ ]Mechanisms and strategies for effective delivery of antisense and siRNA - 2008.pdf2010-01-14 16:17 1.3M 
[ ]Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain - 1994.pdf2010-01-14 16:01 799K 
[ ]In vivo selection yields AAV-B1 capsid for central nervous system and muscle gene therapy - 2016.pdf2018-03-16 09:57 3.2M 
[ ]Intensive pharmacological immunosuppression allows for repetitive liver gene transfer with recombinant adenovirus in nonhuman primates - 2010.pdf2018-03-17 13:36 1.2M 
[ ]Immune responses to AAV vectors: overcoming barriers to successful gene therapy - 2013.pdf2017-04-14 06:30 1.5M 
[ ]Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics.pdf2010-01-14 15:55 934K 
[ ]How to name and classify your phage: an informal guide - 2017.pdf2017-02-26 09:33 310K 
[ ]Genome-editing technologies for gene and cell therapy - 2016.pdf2016-07-26 10:37 927K 
[ ]Gene transfer in humans using a conditionally replicating lentiviral vector.pdf2010-01-14 15:54 648K 
[ ]Gene therapy using adeno-associated virus vectors - 2008.pdf2016-07-26 10:51 970K 
[ ]Gene therapy for red-green color blindness in adult primates - 2009.pdf2011-01-22 14:58 1.1M 
[ ]Gene therapy clinical trials worldwide to 2007—an update.pdf2010-06-17 01:38 574K 
[ ]Gene therapy clinical trials worldwide 1989-2004.pdf2010-06-18 19:39 106K 
[ ]Gene doping - a review of performance-enhancing genetics.pdf2018-04-13 06:31 327K 
[ ]Flushing out antibodies to make AAV gene therapy available to more patients - 2013.pdf2018-03-16 09:51 1.2M 
[ ]FDA Public Workshop on Cell and Gene Therapy - Agenda - November 2010.pdf2011-01-16 06:30 179K 
[ ]Engineering targeted viral vectors for gene therapy - 2007.pdf2010-01-14 16:23 529K 
[ ]Engineering adeno-associated viruses for clinical gene therapy - 2015.pdf2016-07-26 10:42 625K 
[ ]Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer.pdf2010-01-14 15:53 674K 
[ ]Emerging issues in AAV-mediated in vivo gene therapy - 2018.pdf2018-03-16 10:14 1.5M 
[ ]Efficient siRNA delivery into primary cells by a peptide transduction domain-dsRNA binding domain fusion protein.pdf2010-01-14 16:18 438K 
[ ]Efficient gene delivery to the adult and fetal CNS using pseudotyped non-integrating lentiviral vectors.pdf2009-08-12 07:44 1.0M 
[ ]Effective depletion of pre-existing anti-AAV antibodies requires broad immune targeting - 2017.pdf2017-10-13 04:48 2.3M 
[ ]Ectopic Catalase Expression in Mitochondria by Adeno-Associated Virus Enhances Exercise Performance in Mice.pdf2010-01-17 08:12 698K 
[ ]Delivery technologies for genome editing - 2017.pdf2017-04-07 19:44 893K 
[ ]Current status of nonviral vectors for gene therapy in China - 2017.pdf2018-02-03 18:42 360K 
[ ]Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1.pdf2010-01-14 15:52 1.2M 
[ ]Construction of a Fully Retargeted Herpes Simplex Virus 1 Recombinant Capable of Entering Cells Solely via Human Epidermal Growth Factor Receptor 2.pdf2010-01-14 16:25 459K 
[ ]Cell penetrating peptides - overview and applications to the delivery of oligonucleotides.pdf2010-01-14 16:22 392K 
[ ]Cancer regression in patients after transfer of genetically engineered lymphocytes.pdf2010-01-14 15:51 572K 
[ ]CNS-restricted transduction and CRISPR-Cas9-mediated gene deletion with an engineered AAV vector - 2016.pdf2018-03-15 19:47 5.2M 
[ ]CAV-2 - why a canine virus is a neurobiologist's best friend - 2015.pdf2016-03-08 02:12 566K 
[ ]A single-molecule view of genome editing proteins: Biophysical mechanisms for TALEs and CRISPR-cas9 - 2017.pdf2017-05-11 18:36 3.6M 
[ ]A sight on the current nanoparticle-based gene delivery vectors - 2014.pdf2017-01-10 07:05 654K 
[ ]Adeno-associated virus vectors and neurological gene therapy - review - 2014.pdf2016-07-26 10:35 56K 
[ ]Adeno-associated virus serotypes - vector toolkit for human gene therapy - 2006.pdf2010-01-14 16:02 235K 
[ ]A 10 patient case report on the impact of plasmapheresis upon neutralizing factors against adeno-associated virus (AAV) types 1, 2, 6, and 8 - 2011.pdf2018-03-16 09:50 132K 
Apache/2.4.25 (Debian) Server at diyhpl.us Port 80